Véronique Dièras
- Oncology top 0.02%
- Cancer Treatment and Pharmacology 158
- HER2/EGFR in Cancer Research 130
- Lung Cancer Research Studies 26
- Cancer Research top 0.05%
- Breast Cancer Treatment Studies 56
- Cancer Genomics and Diagnostics 36
- Pulmonary and Respiratory Medicine top 0.05%
- Advanced Breast Cancer Therapies 147
- Brain Metastases and Treatment 35
- Lung Cancer Treatments and Mutations 24
- Genetics top 0.2%
Véronique Dièras
344 papers receiving 22.8k citations
Hit Papers
Peers
Comparison fields: 5 of 131
- Oncology 18.5k
- Cancer Research 6.3k
- Pulmonary and Respiratory Medicine 9.5k
- Genetics 2.3k
- Radiology, Nuclear Medicine and Imaging 3.1k
Countries citing papers authored by Véronique Dièras
This map shows the geographic impact of Véronique Dièras's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Véronique Dièras with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Véronique Dièras more than expected).
Fields of papers citing papers by Véronique Dièras
This network shows the impact of papers produced by Véronique Dièras. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Véronique Dièras. The network helps show where Véronique Dièras may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Véronique Dièras, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 1 | |
| 4 | 2024 | 2 | |
| 5 | 2024 | 5 | |
| 6 | 2023 | 1 | |
| 7 | 2023 | 2 | |
| 8 | 2023 | 28 | |
| 9 | 2023 | 4 | |
| 10 | 2020 | 144 | |
| 11 | 2019 | 7 | |
| 12 | 2018 | 105 | |
| 13 | 2016 | 11 | |
| 14 | 2014 | 59 | |
| 15 | 2013 | 148 | |
| 16 | 2012 | 55 | |
| 17 | Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancerbreakdown → | 2012 | 2665 |
| 18 | 2007 | 46 | |
| 19 | [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects]. | 2004 | 8 |
| 20 | 1999 | 2 |
About Véronique Dièras
Véronique Dièras is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 354 papers that have together received 23.3k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (158 papers), Advanced Breast Cancer Therapies (147 papers), HER2/EGFR in Cancer Research (130 papers), Breast Cancer Treatment Studies (56 papers), Cancer Genomics and Diagnostics (36 papers), Brain Metastases and Treatment (35 papers), Lung Cancer Research Studies (26 papers) and Lung Cancer Treatments and Mutations (24 papers). The work is most often cited by research in Oncology (18.5k citations), Cancer Research (6.3k citations) and Pulmonary and Respiratory Medicine (9.5k citations). Véronique Dièras has collaborated with scholars based in France, United States and Germany. Frequent co-authors include Hope S. Rugo, Seock‐Ah Im, Ian E. Krop, Sherene Loi, Sylvia Adams, Mark D. Pegram, Hiroji Iwata, Carlos H. Barrios, Eric P. Winer and Leisha A. Emens. Their work appears in journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.